{"status":"success","data":{"title":"Atrial Fibrillation and Anticoagulation","slug":"atrial-fibrillation","tags":["aspirin","warfarin"],"collection":["Cardiovascular"],"content":"<h1 id=\"atrial-fibrillation-and-anticoagulation\">Atrial Fibrillation and Anticoagulation</h1>\n<ul>\n<li>Anticoagulation goal with <span class=\"drug\">warfarin</span>: INR 2-3</li>\n<li>If age &lt; 60 years and zero risk factors: No anticoagulation b/c low risk for CVA </li>\n</ul>\n<p><strong>Deciding on whether to anticoagulate with aspirin or warfarin:</strong></p>\n<h2 id=\"weak-risk-factors\">Weak Risk Factors</h2>\n<ul>\n<li>Female gender    </li>\n<li>Age 65-74         </li>\n<li>CAD               </li>\n<li>Thyrotoxicosis</li>\n</ul>\n<p><strong>Treatment</strong></p>\n<ul>\n<li><span class=\"drug\">warfarin</span> or <span class=\"drug\">warfarin</span></li>\n</ul>\n<h2 id=\"moderate-risk-factors\">Moderate Risk Factors</h2>\n<ul>\n<li>Age &gt; 75            </li>\n<li>HTN                     </li>\n<li>Heart failure           </li>\n<li>LVEF ≤ 35%              </li>\n<li>DM  </li>\n</ul>\n<p><strong>Treatment</strong></p>\n<ul>\n<li>1 Risk factor: <span class=\"drug\">aspirin</span> or <span class=\"drug\">warfarin</span></li>\n<li>&gt; 1 Risk factor: <span class=\"drug\">warfarin</span></li>\n</ul>\n<h2 id=\"high-risk-factors\">High Risk Factors</h2>\n<ul>\n<li>Prior CVA        </li>\n<li>Prior TIA         </li>\n<li>Embolism          </li>\n<li>Mitral stenosis   </li>\n<li>Mech heart valve</li>\n</ul>\n<p><strong>Treatment</strong></p>\n<ul>\n<li><span class=\"drug\">warfarin</span></li>\n</ul>\n<p>(<a href=\"http://circ.ahajournals.org/content/114/7/e257.full\">AHA/ACC/ESC 2006 guidelines</a>)</p>\n<h2 id=\"background\">Background</h2>\n<p><strong>Atrial Fibrillation</strong> (AF) = <strong>5x</strong> risk for CVA and increases with age </p>\n<ul>\n<li>Patients with persistent and paroxysmal atrial fibrillation should be treated the same when it comes to deciding about anticoagulation. They have an equivalent risk of stroke.</li>\n</ul>\n<p><strong>Stroke risk factors for patients with AF: </strong></p>\n<ul>\n<li>Prior CVA or TIA</li>\n<li>HTN</li>\n<li>Age ≥75</li>\n<li>CHF</li>\n<li>Poor LV function</li>\n<li>DM</li>\n</ul>\n<h2 id=\"chads2-stroke-risk-stratification-scheme\">CHADS2 stroke risk stratification scheme</h2>\n<ul>\n<li><strong>C</strong> = Congestive heart failure (1 pt)</li>\n<li><strong>H</strong> = Hypertension (1 pt)</li>\n<li><strong>A </strong>= Age ≥ 75 (1 pt)</li>\n<li><strong>D </strong>= DM (1 pt)</li>\n<li><strong>S2</strong> = prior Stroke or TIA (2 pts)</li>\n</ul>\n<p><img src=\"https://d2p53dh3qxfm0x.cloudfront.net/uploads/img/1jx/5/m/41833411-397e-52ca-866b-0fe62dacc52e/640.png\" alt=\"\">\n(<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=11401607\">Gage et al., JAMA, 2001</a>)</p>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"http://circ.ahajournals.org/content/114/7/e257.full\">ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation</a></li>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=19111769\">Waldo AL. Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation. Cardiol Clin 2009; 27:125-35.</a></li>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=11401607\">Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.</a></li>\n</ul>\n"}}